Comparing Sildenafil Alone Vs. Sildenafil Plus Brief Couple Sex Therapy on Erectile Dysfunction and Couples' Sexual and Marital Quality of Life: A Pilot Study

Aubin, Sylvie; Heiman, Julia R.; Berger, Richard E.; Murallo, A V; Liu, Yung-Wen

doi:10.1080/00926230802712319

Cited by 70 publications

(41 citation statements)

References 31 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 40 included publications reported findings from 32 RCTs of PDE5 inhibitor treatment of men with ED. There were 28 single‐ or double‐blind, placebo‐controlled, parallel‐group trials [9,16,20–45], one treatment‐controlled, parallel group trial [46], and three open‐label trials [15,47,48]. In addition, there were five pooled analyses of RCT data [14,49–52] and three secondary or subgroup analyses of RCT data [53–55].…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review of the Psychosocial Outcomes Associated with Erectile Dysfunction: Does the Impact of Erectile Dysfunction Extend Beyond a Man's Inability to Have Sex?

McCabe

Althof

2014

The Journal of Sexual Medicine

100

View full text Add to dashboard Cite

Aim The aim of this study was to report and analyze the published data from randomized controlled trials (RCTs) for (i) the psychosocial outcomes associated with erectile dysfunction (ED) before treatment with a phosphodiesterase type 5 (PDE5) inhibitor; and (ii) the change in psychosocial outcomes after the use of a PDE5 inhibitor in men with ED. Methods The method used was a prospectively designed systematic literature review of publications reported in MEDLINE via PubMed, EMBASE, the Cochrane Library, Science Citation Index Expanded, and PsychINFO from January 1, 1995 to May 14, 2012. Main Outcome Measures The main outcome measures were scores on psychosocial measures in men who were treated for ED with a PDE5 inhibitor before and after treatment. Results A total of 1,714 publications were retrieved; 1,674 publications were excluded because they did not meet the design requirements of the review, and 40 publications (32 RCTs) were retained. Before treatment, men who participated in clinical trials reported relatively good quality of life and overall relationships, but poor sexual relationships and sexual satisfaction, diminished confidence, low self-esteem, and symptoms of depression. After treatment, there were significant improvements from baseline in most of these measures, except for overall life satisfaction and overall relationship satisfaction. Conclusions ED and the treatment of ED are associated with substantially broader aspects of a man's life than just erectile functioning. This review demonstrates the importance of evaluating the psychosocial factors associated with ED and its treatment, and the importance of using standardized scales to conduct this evaluation. Further research is needed to better understand the mechanisms underlying the reciprocal relationships among physical and psychological functioning in men with ED.

show abstract

Section: Resultsmentioning

confidence: 99%

A Systematic Review of the Psychosocial Outcomes Associated with Erectile Dysfunction: Does the Impact of Erectile Dysfunction Extend Beyond a Man's Inability to Have Sex?

McCabe

Althof

2014

The Journal of Sexual Medicine

100

View full text Add to dashboard Cite

show abstract

“…For ED, combined treatments have also been found to be more effective than either medical or psychological treatments alone [167,247,248]. Factors that are not addressable by pharmacotherapy alone can be attended to such as: (i) patient factors (performance anxiety, self-confidence); (ii) partner factors (partner sexual dysfunction); (iii) relationship factors (conflict, lack of communication); (iv) sexual factors in the relationship (sexual scripts, sexual satisfaction); and (v) contextual factors (life stressors).…”

Section: Combining Psychological and Pharmacological Treatmentmentioning

confidence: 99%

An Update of the International Society of Sexual Medicine's Guidelines for the Diagnosis and Treatment of Premature Ejaculation (PE)

Althof¹,

McMahon²,

Waldinger³

et al. 2014

The Journal of Sexual Medicine

256

321

View full text Add to dashboard Cite

Introduction. In 2009, the International Society for Sexual Medicine (ISSM) convened a select panel of experts to develop an evidence-based set of guidelines for patients suffering from lifelong premature ejaculation (PE). That document reviewed definitions, etiology, impact on the patient and partner, assessment, and pharmacological, psychological, and combined treatments. It concluded by recognizing the continually evolving nature of clinical research and recommended a subsequent guideline review and revision every fourth year. Consistent with that recommendation, the ISSM organized a second multidisciplinary panel of experts in April 2013, which met for 2 days in Bangalore, India. This manuscript updates the previous guidelines and reports on the recommendations of the panel of experts. Aim. The aim of this study was to develop clearly worded, practical, evidenced-based recommendations for the diagnosis and treatment of PE for family practice clinicians as well as sexual medicine experts. Method. A comprehensive literature review was performed.Results. This article contains the report of the second ISSM PE Guidelines Committee. It offers a new unified definition of PE and updates the previous treatment recommendations. Brief assessment procedures are delineated, and validated diagnostic and treatment questionnaires are reviewed. Finally, the best practices treatment recommendations are presented to guide clinicians, both familiar and unfamiliar with PE, in facilitating treatment of their patients. Conclusion. Development of guidelines is an evolutionary process that continually reviews data and incorporates the best new research. We expect that ongoing research will lead to a more complete understanding of the

show abstract

“…In summary, the primary-care physician is ideally poised to help patients with ED and their partners by assessing the problem; providing sound education, including a focus on pleasure and arousal (via more prolonged foreplay and sensuality) rather than erection; and ⁄ or referring couples to a sex therapist, psychotherapist or marriage counsellor, as needed (99). Finally, medical therapy and counselling couples or psychosexual therapy are not mutually exclusive; recent evidence suggests that a combination of such therapies can enhance sexual satisfaction, intimacy and cognition in men with ED and their female partners (100).…”

Section: Special Case For Evaluation Education and Expectations: Impmentioning

confidence: 99%

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction

Sadovsky

Brock

Gutkin³

et al. 2009

International Journal of Clinical Practice

View full text Add to dashboard Cite

Despite the marked adverse impacts of erectile dysfunction (ED) on quality of life and well-being, many patients (and/or their partners) do not seek medical attention for this problem, do not receive treatment or discontinue such treatment even when it has effectively restored erectile responses to sexual stimulation. Phosphodiesterase type 5 (PDE5) inhibitors are considered first-line therapies for men with ED. To help physicians maximise the likelihood of treatment success with these agents, we conducted an English-language PubMed search of articles involving approved PDE5 inhibitors dating from 1 January 1998 (the year in which sildenafil citrate was introduced), through 31 August 2008. In addition to sildenafil, tadalafil and vardenafil, search terms included ‘adhere*’, ‘couple*’, ‘effect*’, ‘effic*’, ‘partner*’, ‘satisf*’, ‘succe*’ and ‘treatment outcome.’ Based on our analysis, physician activities to promote favourable treatment outcomes may be captured under the mnemonic ‘EPOCH’: (i) Evaluating and educating patients and partners to ensure realistic expectations of therapy; (ii) Prescribing a treatment individualised to the couple’s lifestyle needs and other preferences; (iii) Optimising treatment outcomes by scheduling follow-up visits with the patient to ‘fine-tune’ dosages and revisit key educational messages; (iv) Controlling comorbidities via lifestyle counselling, medications and/or referrals and (v) Helping patients and their partners to meet their health and psychosocial needs, potentially referring them to a specialist for other forms of therapy if they are not satisfied with PDE5 inhibitors.

show abstract

Comparing Sildenafil Alone Vs. Sildenafil Plus Brief Couple Sex Therapy on Erectile Dysfunction and Couples' Sexual and Marital Quality of Life: A Pilot Study

Cited by 70 publications

References 31 publications

A Systematic Review of the Psychosocial Outcomes Associated with Erectile Dysfunction: Does the Impact of Erectile Dysfunction Extend Beyond a Man's Inability to Have Sex?

A Systematic Review of the Psychosocial Outcomes Associated with Erectile Dysfunction: Does the Impact of Erectile Dysfunction Extend Beyond a Man's Inability to Have Sex?

An Update of the International Society of Sexual Medicine's Guidelines for the Diagnosis and Treatment of Premature Ejaculation (PE)

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction

Contact Info

Product

Resources

About